Now Playing
Physical AI, GSK's $10.6B Bet & SPV Access: Where Capital Is Concentrating
Audio is available on Spreaker — see link below.
Industrial robots, defense satellites, and pharma acquisitions are pulling venture capital away from consumer AI — and this week's numbers make the shift undeniable. Today's briefing covers Standard Bots' $200M raise, ICEYE's €450M round, GSK's Nuvalent acquisition, Gilead's split results, and Sabertooth Capital's $500M SPV play.
Audio is available on Spreaker — see link below.
Physical AI is pulling ahead of consumer AI in venture capital, and the numbers from this week make that hard to argue with. Standard Bots just closed a two hundred million dollar Series C for industrial robot arms.
ICEYE's raise tells a similar story from a different angle. General Atlantic led the round, bringing ICEYE's lifetime funding to one point three billion euros.
Pharma is running its own version of this consolidation story. GSK acquired Nuvalent for ten point six billion dollars.
Gilead had a split week that illustrates the execution variance well. The Gilead-Merck once-weekly HIV pill cleared Phase Three.
One more development worth watching: Sabertooth Capital deployed five hundred million dollars into late-stage startups via special purpose vehicles, with positions in Anthropic, Anduril, Databricks, and SpaceX. No traditional fund structure.
The through-line across all of this is consolidation. Capital is concentrating in infrastructure, in late-stage assets, and in deals where there's a strategic rationale beyond pure commercial return.
Chapter summary auto-generated from the verified script. Listen to the full episode for the complete content.